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Abstract
Introduction: Short stature homeobox-containing gene 
(SHOX) haploinsufficiency is associated with short stature, 
Madelung deformity and mesomelia. Current clinical screen-
ing tools are based on patients with intragenic variants or 
deletions. However, recent discoveries showed that dele-
tions of the enhancer elements are quite common. The ma-
jority of these patients show less body disproportion and re-
spond better to recombinant human growth hormone treat-
ment. We redefined clinical criteria for genetic analysis to 
facilitate detection of the full spectrum of SHOX haploinsuf-
ficiency. Methods: We analyzed 51 children with SHOX vari-
ants or deletions and 25 children with a deletion in its en-
hancer region. Data were compared to 277 children referred 
for suspicion of growth failure without endocrine or genetic 
pathology. Results: Only half of the patients with an enhanc-
er region deletion fulfilled any of the current screening crite-
ria. We propose new clinical criteria based on sitting height 
to height ratio > 1 SDS or arm span ≥3 cm below height, with 
a sensitivity of 99%. When these criteria are combined with 
obligatory short stature, the sensitivity to detect SHOX hap-
loinsufficiency is 68.1%, the specificity 80.6%, and the num-
ber needed to screen 21 patients. Conclusion: Novel clinical 
criteria for screening for SHOX haploinsufficiency allow the 
detection of patients within the full genetic spectrum, that 
is, intragenic variants and enhancer region deletions.
© 2020 The Author(s)
Published by S. Karger AG, Basel
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NonCommercial-NoDerivatives 4.0 International License (CC BY-
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Introduction
The short stature homeobox-containing gene (SHOX) 
on the pseudoautosomal region 1 of chromosomes X and 
Y encodes a transcription factor that regulates temporal 
and spatial expression of genes involved in linear growth 
[1]. SHOX function is dose dependent: a homozygous loss 
of SHOX expression results in a severe skeletal dysplasia 
(Langer mesomelic dysplasia [2–4]), a heterozygous loss 
of SHOX expression (SHOX haploinsufficiency) leads to a 
wide phenotypic spectrum [5–8], while duplication of 
SHOX leads to tall stature [9]. At one side of the spectrum 
of SHOX haploinsufficiency, there are patients with clas-
sical Leri-Weill dyschondrosteosis, typically presenting 
with short stature, Madelung deformity, mesomelia, cubi-
tus valgus, bowing of the forearm, muscular hypertrophy, 
dislocation of the ulna, and typical radiological signs (e.g., 
triangulation of distal radial epiphyses, wedging of carpal 
bones, metaphyseal lucency). On the other side of the 
spectrum, one can encounter individuals with only mild 
body disproportions, and in some cases, even a height in 
the lower half of the height distribution of the population 
growth charts with normal body proportions. Even within 
the same family, considerable phenotypic and radiologic 
heterogeneity exist [10–15]. Causes of SHOX haploinsuf-
ficiency include heterozygous deletions or variants in the 
SHOX gene itself, heterozygous deletions of (part of) one 
of the 5′ or 3′ enhancer regions regulating SHOX expres-
sion, or duplications in these regions inhibiting proper ex-
pression [16]. SHOX haploinsufficiency has been found in 
2–17% of children who initially were considered as having 
“idiopathic short stature,” making it the most frequent 
monogenetic cause of short stature [12, 16–19]. Patients 
with SHOX haploinsufficiency benefit from treatment 
with recombinant human GH [7, 20–22] and from follow-
up for development of Madelung deformity. 
Several screening tools have been developed to guide 
clinicians in whom to screen for SHOX haploinsufficien-
cy, such as extremities to trunk ratio (ETR) [23] or the sit-
ting height to standing height (SH/H) ratio [8]. In 2007, 
Rappold et al. [10] suggested using a combination of body 
disproportions (arm span to height ratio < 96.5% and 
SH/H ratio > 55.5%) and cubitus valgus, bowing of the 
forearm, body mass index, dislocation of the ulna, muscu-
lar hypertrophy, and short forearm, with a reported sen-
sitivity of 71% for a score of > 4 out of 24 points. Hirschfel-
dova et al. [24] also concluded that the level of dispropor-
tion and typical signs of SHOX haploinsufficiency at 
clinical evaluation were most specific of intragenic SHOX 
defects. In 2013, Wolters et al. [25] tested several scoring 
systems in a cohort of 22 children with SHOX haploinsuf-
ficiency and reported a sensitivity of the Rappold cutoffs 
for arm span to height ratio and SH/H of 73 and 59%, re-
spectively, for a Rappold score > 4 points of 73%, and for 
a decreased ETR (as defined by Binder et al. [23]) of 59%. 
Notably, most of these scoring systems were formu-
lated based on patients with intragenic SHOX defects (al-
though Wolters et al. [25] included 3 children with SHOX 
enhancer region deletions). However, in the past decade, 
it has become evident that SHOX enhancer region dele-
tions are quite common in patients with SHOX haploin-
sufficiency, occurring in roughly 15–40% [16], and these 
patients usually show less body disproportion [7, 26–32] 
and a greater response to recombinant human growth 
hormone (rhGH) [7]. Recently, Genoni et al. [33] ana-
lyzed 19 patients with SHOX haploinsufficiency, with half 
of them having SHOX enhancer region deletions. They 
concluded that the sensitivity of the Rappold score was 
only 37% in the total group and suggested including low 
growth velocity (below –1.5 SDS) to increase the sensitiv-
ity to 89.5%. 
In light of the recent widening of the phenotype of 
SHOX haploinsufficiency, and taking into consideration 
the decreasing costs of genetic analysis, the high preva-
lence of intragenic SHOX defects or deletions of its en-
hancer region in children with short stature and the pos-
itive effects of early rhGH treatment on adult height, we 
aimed at redefining screening criteria for genetic analysis 
for the full spectrum of SHOX haploinsufficiency based 
on our observations in a large group of patients with ei-
ther intragenic SHOX defects or deletions of its enhancer 
region, in order to obtain a higher sensitivity. For this 
purpose, we reanalyzed the auxological data of the pa-
tients from our previous publication [7], as well as data 
from children referred to a pediatric outpatient clinic for 
suspected growth failure, in whom no endocrine or ge-
netic pathology was found [34, 35].
Subjects and Methods
Patients
In this retrospective analysis, we included patients under the 
age of 18 with pathogenic defects of SHOX or its enhancer region, 
diagnosed between 2002 and 2014 in the Leiden University Medi-
cal Center, Erasmus Medical Center in Rotterdam, VU University 
Medical Center in Amsterdam, and University Medical Center 
Groningen in the Netherlands. None of the patients were on GH 
treatment at the time of evaluation. Patients were excluded in case 
of incomplete clinical data or comorbidity that could contribute to 
short stature. In a first analysis, the data were used to describe the 
clinical features of the various genetic subgroups and the response 
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to GH treatment [7]. Height and sitting height were measured us-
ing a wall-mounted stadiometer and weight with a digital floor 
scale. Arm span was measured by placing the patient against a wall 
with arms spread, marking the arm span on the wall, and subse-
quently using a measuring tape.
Control Subjects
In order to calculate the specificity of the clinical score, we an-
alyzed auxological data from a database of 277 children referred to 
the pediatric outpatient clinic for suspected growth failure in the 
Tergooi Hospital, in whom no endocrine or genetic pathology was 
found. Referral criteria were short stature or decreased growth ve-
locity. Patients were screened for SHOX haploinsufficiency in case 
of a Rappold score above 8 points or typical clinical and radiolog-
ical features of Leri-Weil dyschondrosteosis. Excluded were ad-
opted children and children with ethnicities for which no Dutch 
growth references are available (so those with another ethnicity 
than Dutch, North African, or South-Eastern European). A full 
description of this cohort, which includes head circumference, 
arm span, and SH/H ratio, has been reported previously [34, 35].
Genetic Analysis
DNA isolation and Sanger sequencing of the complete coding 
region, including intron-exon boundaries, were performed using 
standard procedures (PCR primers and conditions available upon 
request). Multiplex Ligation-dependent probe amplification was 
performed according to the manufacturer’s instructions (MRC-
Holland, Amsterdam, The Netherlands). See online supplemen-
tary Table 1 (see www.karger.com/doi/10.1159/000507215 for all 
online suppl. material) for characterization of the variants. 
In 73 patients, variants were classified as pathogenic, and in 3 
patients, a variant of uncertain significance (VUS) was detected. 
Two of these 3 patients harbor the same 5′ enhancer deletion, which 
has been previously associated with clinical features of SHOX hap-
loinsufficiency [26, 29, 36, 37]. Both show phenotypical features of 
SHOX haploinsufficiency (as well as the affected father of one of 
them). The third patient carries a missense VUS based on the 
American College of Medical Genetics and Genomics/Association 
for Molecular Pathology classification, which has only been seen in 
1 individual in a control population (MAF 0.00083%, for details see 
online suppl. Table 1); this patient and his affected father show a 
clinical phenotype consistent with SHOX haploinsufficiency. A re-
cent report emphasizes that the clinical phenotype of a well-de-
scribed disorder, as well as the frequency in publicly available data 
bases of normal individuals, should be taken into account when 
assessing the pathogenicity of variants, as they display a more real-
istic reflection of daily practice [38]. To allow the readership to 
compare the auxological data of these 3 cases to those carrying 
pathogenic variants, data from the 3 patients carrying likely patho-
genic variants are marked with gray symbols in all relevant figures.
Statistical Analysis
Dutch nation-wide reference data were used to calculate SDS 
for height and SH/H ratio [39, 40] and body mass index [41]. Birth 
weight SDS was calculated using Niklasson et al. [42]. The ETR 
represents the sum of the subischial length and arm span, divided 
by sitting height [23]. The Binder et al. [23] criterion for decreased 
ETR was defined as being lower than 1.95 + 1/2 • height in meters. 
To assess whether information about height SDS of the parent car-
rying the SHOX (enhancer) defect and the noncarrier parent con-
tributes to the decision which child should be tested for SHOX 
haploinsufficiency, we calculated the correlation between height 
SDS of the patient and their (non-)carrier parent.
Statistical significance of mean differences between groups was 
tested using the two-tailed independent Student t test or, in case 
the assumption of normality was not met (Shapiro-Wilk test), the 
Mann-Whitney U test. Categorical data were compared using the 
chi-square test or, when the expected cell count was < 5, the Fisher’s 
exact test. Associations were tested using Pearson’s correlation. 
Linear regression was used to correct the associations between pa-
tient and affected parent features for variant type, gender, and 
height of unaffected parent, and to correct the difference between 
the ETR between patients and controls for height. Differences were 
considered statistically significant at p < 0.05. Receiver operation 
characteristic curves were calculated to assess the relationship be-
tween sensitivity and 1-specificity for various potential predictors 
of SHOX haploinsufficiency. 
Results
Clinical Characteristics (Table 1)
We obtained data from 76 patients with either a vari-
ant (n = 11) or deletion (n = 40) in SHOX, or a deletion 
in the downstream (n = 23) or upstream (n = 2) enhancer 
of SHOX (Table 1). Average age at evaluation was 8.4 
years (range 1.2–16.2 years). Typical clinical and radio-
logical features of Leri-Weil dyschondrosteosis (e.g., 
Madelung deformity) were not routinely reported. Aver-
age height was –2.5 SDS (range –4.4 to –0.3 SDS), with 
height below –2 SDS in 71.1% of patients and below –1 
SDS in 97.4%. In addition, data from 277 control subjects 
referred for a suspicion of growth failure to a non-aca-
demic growth clinic, in whom no endocrine or genetic 
pathology was found, were included (Table 1). Controls’ 
average age was 10.4 years (range 3.1–18.0 years), average 
height –1.9 SDS (range –3.2 to 1.0 SDS), with height be-
low –2 SDS in 43.7% and below –1 SDS in 89.9%. Controls 
differed significantly from patients in height SDS, target 
height SDS, body mass index SDS, arm span to height ra-
tio, arm span minus height, and SH/H ratio SDS. Also, 
average age in controls was 2.0 years older, and the per-
centage of females was lower. 
As can be observed in Figure 1, height SDS alone is a 
poor predictor of SHOX defects, with an area under the 
curve (AUC) of 0.717 and the optimal cutoff between 
–2.75 SDS and –1.75 SDS. A cutoff of height below –2.0 
SDS was chosen because these children will likely benefit 
most from treatment with rhGH, yielding a sensitivity of 
71.1% and specificity of 56.3%. 
Average SH/H ratio of all patients was 2.8 SDS (range 
0.2–5.5 SDS). Compared to patients with SHOX enhancer 
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region deletions, patients with intragenic SHOX defects 
had significantly higher SH/H ratio (mean difference ± 
SEM 1.17 ± 0.30, p < 0.001). All patients had a SH/H ratio 
> 0 SDS, 94.2% a ratio > 0.5 SDS, and 89.9% a ratio > 1.0 
SDS. SH/H ratio was strongly correlated with age in pa-
tients and controls (p < 0.001 in both). The Rappold score 
criterion of SH/H > 55% has a sensitivity of 76.8% in pa-
tients with SHOX haploinsufficiency (83.3% in patients 
with intragenic SHOX defects, 61.9% in those with en-
hancer region deletions). SH/H ratio SDS was a good pre-
dictor of a SHOX defect, with an AUC of 0.913 (Fig. 1). 
We chose a cutoff of SH/H ratio >+1.0 SDS to optimize 
sensitivity (89.9%) with reasonable specificity (75.1%).
For 32 patients with sufficient data, Figure 2a shows 
that the arm span minus height is < 0 in 90.6% and ≤–3 
cm in 84.4%. When the arm span to height ratio is used 
(Fig. 2b), the Rappold score cutoff of < 96.5% cm yields a 
sensitivity of 68.8% (80.0% in intragenic SHOX defects 
and 50.0% in enhancer region deletions). Although both 
the ratio and the arm span minus height are known to 
exhibit a slight association with age [43, 44], as was also 
present in our control cohort (r = 0.327 and r = 0.281, re-
spectively), no statistical significant association was ob-
served in our patients (p = 0.175 and p = 0.849, respec-
tively). Figure 3 shows the ETR, which was significantly 
lower in patients with intragenic SHOX defects compared 
to those with enhancer region deletions (mean difference 
± SEM 0.14 ± 0.06, p = 0.028). Using the Binder criterion, 
71.0% of patients had a decreased ETR (85.0% in patients 
with intragenic SHOX defects, 45.5% in those with en-
hancer region deletions). Specificity of the Binder crite-
rion was 89.6%. Figure 1 shows that, although the ETR 
performs better in the low sensitivity range, all 3 param-
eters that use arm span show equal AUC for sensitivities 
above 80%. Given the elaborate calculation of the ETR 
and easier interpretation of the arm span minus height 
compared to its ratio, we chose the arm span minus height 
as a screening criterion for SHOX haploinsufficiency. A 
cutoff of ≤–3 cm yields a high sensitivity of 84.4% with a 
reasonable specificity of 73.6%.
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Table 1. Clinical characteristics of patients and control subjects
Number† All patients with 
SHOX 
haploinsufficiency
Number† SHOX variants 
or deletions
Number† SHOX upstream or 
downstream enhancer 
deletions
Number† Control 
subjects
Age, years 76 8.4±3.6 51 8.3±3.5 25 8.6±3.7 277 10.4±3.9*
Females, % 76 57 51 55 25 60 277 43*
Birth weight SDS 64 –0.4±1.3 41 –0.5±1.3 23 –0.3±1.3 277 –0.3±1.1
Height SDS 76 –2.5±0.8 51 –2.6±0.8 25 –2.3±0.8 277 –1.9±0.7*
Target height SDS 71 –1.0±0.6 47 –1.1±0.6 24 –0.9±0.5 277 –0.4±0.60*
BMI, kg/m2 SDS 73 0.4±1.0 49 0.6±0.9 24 –0.2±1.0 277 –0.3±1.1*
Arm span/height ratio 32 0.95±0.02 20 0.95±0.02 12 0.96±0.03 254 0.99±0.03*
Arm span minus height, cm 32 –5.5±3.0 20 –5.7±3.0 12 –5.1±3.1 254 –1.0±3.6*
SH/H SDS 69 2.8±1.3 48 3.2±1.1 21 2.0±1.2** 261 0.4±0.9*
ETR‡ 32 2.5±0.2 21 2.4±0.2 11 2.6±0.2** 250 2.8±0.2*
Data are presented as mean ± SD. † Number of persons with available data. ‡ Differences corrected for height using linear regression. * Difference be-
tween control subjects and patients with SHOX haploinsufficiency statistically significant at p < 0.05. ** Difference between patients with SHOX variants or 
deletions and SHOX enhancer deletions statistically significant at p < 0.05. SHOX, Short stature homeobox-containing gene; ETR, extremities to trunk ratio; 
SH/H, sitting height to height; BMI, body mass index.
Fig. 1. Receiver operating characteristic curves illustrating the di-
agnostic ability of several parameters to detect SHOX gene defects. 
The ETR criterion was depicted as ETR –1.95 + 1/2 • height in me-
ters, as used by Binder et al. [23] who suggested a cutoff at zero. 
SH/H, sitting height to height; ETR, extremities to trunk ratio.
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As can be appreciated in Figures 2–6, the 3 patients 
with variants that are classified as a VUS but considered 
as likely or possibly pathogenic (grey symbols) show sim-
ilar characteristics as those classified as pathogenic (black 
symbols). 
The affected parent’s average height was –2.2 ± 0.9 SDS 
(n = 49, < –2 SDS in 57.1%), and median SH/H was 2.3 
SDS (n = 23, interquartile range 1.5–4.2 SDS, > 1 SDS in 
82.6%). No significant correlation (p = 0.655) was ob-
served between height SDS of the patient and the affected 
parent (Fig. 4a). Neither variant type nor gender signifi-
cantly influenced this relation. Height of the unaffected 
parent was not significantly associated with patients’ 
height (p = 0.058, Fig. 4b). Patients’ height SDS signifi-
cantly correlated with target height SDS (p < 0.001, Fig. 4c). 
Combinations of Clinical Characteristics
Height <–2.0 SDS with an SH/H ratio > 1.0 SDS is pres-
ent in only 63.8% of patients (Table 2). Within the subgroup 
of patients with height <–2.0 SDS, however, all had an SH/H 
ratio > 0 SDS, 88% > 1 SDS, and 70% > 2 SDS (Fig. 5). 
Height <–2.0 SDS with arm span minus height ≤–3 cm 
is also present in only a small proportion of patients (56.3%, 
Table 2). Within patients with height <–2.0 SDS and with 
available arm span measurement (n = 20), 90% had an arm 
span minus height of ≤–3 cm and 55% of ≤–5 cm. The 
Binder criterion showed a sensitivity of 65% and a specific-
ity of 90.8% within patients with height <–2.0 SDS.
Figure 6a and Table 2 show that a combined cutoff of 
SH/H ratio > 1.0 SDS and arm span minus height ≤–3 cm 
yields a sensitivity of 77.4% if both criteria are met and 
98.5% if either is met. Within patients with height <–2.0 
SDS (Fig. 6b), sensitivity is 75% if both criteria are met 
and 95.0% if either are (specificity 84.4 and 55.9%, respec-
tively). The combination of arm span to height ratio < 
96.5% with SH/H ratio > 55.5% as suggested by Rappold 
et al. [10] showed a sensitivity of 54.8% (36.4% in SHOX 
enhancer region mutations) and specificity of 95.2%. 
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Fig. 2. Arm span minus height (a) or arm span divided by height (b) for patients with SHOX gene defect (n = 21) 
or SHOX enhancer region deletions (n = 12). Gray symbols denote patients with a genetic variant of unknown 
significance and phenotype suspect for SHOX haploinsufficiency. Dotted lines represent different cutoff points. 
The black square represents the control subjects’ mean and SD. SGD, SHOX gene defect; SED, SHOX enhancer 
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Fig. 3. ETR versus height for patients with SHOX gene defects 
(n = 21) or SHOX enhancer region deletions (n = 10). Gray sym-
bols denote patients with a genetic variant of unknown signifi-
cance and phenotype suspect for SHOX haploinsufficiency. Dotted 
lines represent different cutoff points. The black square represents 
the control subjects’ mean and SD. ETR, extremities to trunk ratio; 
SGD, SHOX gene defect; SED, SHOX enhancer region deletions.
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Proposed Criteria for SHOX Testing
We formulated revised selection criteria for testing for 
SHOX haploinsufficiency (Table 3). We propose to screen 
only those children with a height below –2 SDS (or in case 
of typical clinical features, see below), as these children 
will likely benefit most from rhGH treatment. Next, we 
chose a relatively high sensitivity for the cutoff of the 2 
most distinctive auxological parameters, that is, SH/H 
SDS > 1 or arm span minus height ≤–3 cm. When height 
<–2 SDS is combined with either SH/H SDS > 1 or arm 
span minus height ≤–3 cm, sensitivity for the entire co-
hort is 68.1% (71.7% in intragenic SHOX defects and 
56.5% in enhancer region deletions), specificity 80.6%, 
the positive likelihood ratio 3.5, and the negative likeli-
hood ratio 0.4. Assuming a 2% pretest probability of a 
SHOX defect in children with a height SDS of <–2.0, the 
posttest odds using the total score would be 3.8%, result-
ing in a posttest probability of 6.7%, and a number need-
ed to screen of 21 children. Sensitivity can be improved if 
also children with a height SDS in the lower half of the 
population range are investigated if either their arm span 
minus is ≤–3 cm or SH/H ratio is > 1 SDS.
In addition, typical signs of Leri-Weill dyschondroste-
osis present at physical examination or X-ray are consid-
ered highly specific and should warrant genetic analysis 
in all patients with a height below –1 SDS. Lastly, we ad-
vise to screen patients with short stature (height below –2 
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Fig. 5. SH/H in SDS versus height in SDS for patients with SHOX 
gene defects (n = 48) or SHOX enhancer region deletions (n = 21). 
Gray symbols denote patients with a genetic variant of unknown 
significance and phenotype suspect for SHOX haploinsufficiency. 
Dotted lines represent different cutoff points. The black square 
represents the control subjects’ mean and SD. SH/H, sitting height 
to height; SGD, SHOX gene defect; SED, SHOX enhancer region 
deletions.
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SDS) and a parent with either short stature (height below 
–2 SDS), typical signs of Leri-Weill dyschondrosteosis, or 
specific auxological signs, that is, SH/H > 1 SDS or arm 
span ≥3 cm below height.
Discussion
We aimed to redefine criteria for genetic analysis that 
allow the discovery of pediatric patients with SHOX hap-
loinsufficiency caused by either intragenic SHOX defects 
or deletions of its enhancer region. Based on data from 76 
patients, the largest cohort to date that includes both 
types of SHOX haploinsufficiency, we formulated screen-
ing criteria that incorporate height SDS, SH/H SDS, arm 
span minus height, and typical clinical and radiological 
signs of Leri-Weill dyschondrosteosis (Table 3). 
Previous criteria for genetic analysis were almost exclu-
sively based on cohorts of patients with intragenic SHOX 
defects. However, patients with SHOX enhancer region 
deletions show a milder phenotype with respect to SH/H 
ratio SDS and ETR (Table 1). As a consequence, within the 
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Table 2. Sensitivity, specificity and positive likelihood ratio of auxological criteria and their combinations in patients with SHOX hap-
loinsufficiency and controls
Criterion SHOX defects* Controls* Sensitivity Specificity LR+ LR–
Height SDS <–2.0 54 (76) 121 (277) 71.1 56.3 1.6 0.5
SH/H ratio SDS >+1 62 (69) 64 (261) 89.9 75.5 3.7 0.1
Arm span minus height ≤–3 cm 27 (32) 71 (254) 84.4 72.0 3.0 0.2
Either arm span minus height or SH/H ratio SDS criterion 65 (66) 103 (250) 98.5 58.8 2.4 0.03
Both arm span minus height or SH/H ratio SDS criterion 24 (31) 29 (250) 77.4 88.4 6.7 0.3
Height SDS <–2.0
SH/H ratio SDS >+1 44 (69) 32 (261) 63.8 87.7 5.2 0.4
Arm span minus height ≤–3 cm 18 (32) 34 (254) 56.3 86.6 4.2 0.5
Both criteria 15 (31) 17 (250) 48.4 93.2 7.1 0.6
Either criterion 47 (69) 49 (253) 68.1 80.6 3.5 0.4* Data represent number of patients that fulfil the criterion and in brackets the number of patients with available data for that crite-
rion. SH/H, sitting height to length; LR+, positive likelihood ratio; LR–, negative likelihood ratio; SHOX, short stature homeobox-con-
taining gene.
Fig. 6. Arm span minus height versus SH/H ratio SDS for patients with SHOX gene defects or SHOX enhancer 
region deletions in all patients (a, SGD n = 20, SED n = 11) and in patients with height below –2.0 SDS (b, SGD 
n = 12, SED n = 8). Gray symbols denote patients with a genetic variant of unknown significance and phenotype 
suspect for SHOX haploinsufficiency. Dotted lines represent cutoff points. The black square represents the con-
trol subjects’ mean and SD. SH/H, sitting height to height; SGD, SHOX gene defect; SED, SHOX enhancer region 
deletions.
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group of patients with SHOX enhancer region deletions in 
our cohort, previous criteria such as the Rappold criteria 
for SH/H and arm span/height ratio are met in only 61.9 
and 50.0%, respectively (and if both criteria are met, as 
required for the Rappold criterion of 4 points, in only 
36.4%). The Binder criterion for ETR was met in only 
45.5% [10, 23]. An additional disadvantage of the Rappold 
score is that it does not perform equally in different age 
groups, as the Rappold SH/H ratio criterion is not age de-
pendent despite the strong correlation between SH/H ra-
tio SDS and age (p < 0.001 in patients and controls).
In order to formulate novel screening criteria, several 
auxological parameters were studied in the total cohort of 
patients with intragenic SHOX defects and deletions of its 
enhancer region, aiming for high sensitivity with reason-
able specificity. We used short stature (i.e., height < –2 
SDS) as a starting point, as these children are most likely 
to be referred to the pediatric endocrinologist, and are 
expected to benefit most from treatment with rhGH. 
Within the 71.1% of patients fulfilling this criterion, we 
included the 2 parameters that were most distinctive and 
were irrespective of age; SH/H > 1 SDS or arm span minus 
height ≤–3 cm. These parameters were present in 88 and 
90% of patients with height < –2 SDS, respectively, and 
either one was present in 95%. Genoni et al. [33] reported 
a similar sensitivity of 89.5% in patients with short stature 
using a combination of growth velocity below –1.5 SDS 
and the Rappold score. However, accurate growth veloc-
ity might not be available at first presentation, as was the 
case in most of our patients who were referred to our ter-
tiary centers. We used the difference between arm span 
and height instead of its ratio because the former seems 
more age independent than the latter [43, 45]. Instead of 
separate cutoff limits for SH/H and arm span minus 
height, the ETR can be used. However, this composite 
score does not diagnose SHOX haploinsufficiency better 
than the arm span to height ratio, as shown in the receiv-
er operation characteristic curve, and is more elaborate to 
measure and calculate than the SH/H ratio SDS and arm 
span minus height. As our cohort also incorporated pa-
tients with height above –2 SDS, the sensitivity of the aux-
ological criteria in our total cohort is 68.1%. 
Next, we assessed the association between SHOX hap-
loinsufficiency and parental height and found no correla-
tion between height of the patient and affected parent. 
This implies that factors other than the specific SHOX 
defect explain the variability in height SDS within the 
group of patients with SHOX haploinsufficiency. One 
possible factor could be DNA polymorphisms inherited 
from the unaffected parent, although their height was also 
not significantly associated with that of the patient. Nev-
ertheless, the affected parent often displayed short stature 
or increased SH/H, and we advise to screen for SHOX 
haploinsufficiency in patients with short stature and a 
parent with obvious auxological abnormalities such as 
height <–2 SDS, SH/H > 1 SDS, or arm span ≥3 cm below 
height. Obviously, all patients with typical clinical or ra-
diological signs of SHOX haploinsufficiency and height 
below –1 SDS should also be screened, as these features 
are considered highly specific [24].
Although this study is the first to date that combines 
data from a relatively large group of patients with intra-
genic SHOX defects and deletions of its enhancer region 
to formulate criteria for genetic analysis, there are several 
limitations that need to be addressed. First, using the 
height SDS below –2 SDS for all patients that should be 
screened excludes 28.9% of patients in our cohort. The 
reason we chose this criterion is that most patients re-
ferred to the pediatric endocrinologist for short stature 
will fulfill this criterion, these patients are expected to 
benefit most from rhGH, and within this group the crite-
ria allow the detection of nearly all patients. Nevertheless, 
one must bear in mind that the excluded patients will not 
receive follow-up for the development of Madelung de-
formity (present in 59% of patients with height > –2 SDS), 
or genetic counselling in family planning. This implies 
that clinicians may consider testing for SHOX haploin-
sufficiency if height SDS is in the lower half of the popu-
lation range, and there is a combination of relatively short 
arm span and relatively high SH/H ratio. Second, only 
Table 3. Clinical criteria for testing for variants in SHOX or its en-
hancer region
Test for variants in SHOX or its enhancer region if one of the 
following applies:
– Height below –2 SDS and either SH/H SDS >1 or arm span  
≥3 cm below height
– Height below –1 SDS and typical signs of Leri-Weill 
dyschondrosteosis at either X-ray of hand/wrist/forearm or 
physical examination, that is, Madelung deformity, cubitus 
valgus, short forearm, muscular hypertrophy, dislocation of ulna
– Height below –2 SDS and a parent with either of the following: 
– Height SDS <–2 
– SH/H SDS >1 and arm span ≥3 cm below height 
– Typical signs of Leri-Weill dyschondrosteosis (Madelung 
deformity, etc.,)
SHOX, short stature homeobox-containing gene; SH/H, sitting 
height to height.
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control subjects with a Rappold score of over 8 points or 
typical clinical and radiological features of Leri-Weil dys-
chondrosteosis were screened for SHOX defects. There-
fore, we cannot completely exclude SHOX haploinsuffi-
ciency in the control group. Our estimation of the speci-
ficity may therefore be too conservative. Third, with the 
expanding use of growth-specific gene panels, multiplex 
ligation-dependent probe amplification, and whole 
exome sequencing, criteria for SHOX analysis may be-
come less strict in the upcoming decennia, although one 
should realize that with current techniques whole exome 
sequencing based growth-specific gene panels cannot de-
tect small deletions of the SHOX gene or its enhancers. 
Lastly, 2 variants in 3 patients were classified as likely or 
possibly pathogenic, but all 3 patients (and their affected 
family members) showed the typical disproportions as-
sociated with SHOX haploinsufficiency. A recent report 
calls for the appreciation of the clinical phenotype of pa-
tients suspected to have a well-described clinical syn-
drome when assessing the pathogenicity of their genetic 
variant [38]. This supports a more realistic reflection of 
daily practice, as was the case in our 3 patients that were 
considered SHOX haploinsufficient. As can be observed 
in Figures 2–6, omitting these cases does not significantly 
change the sensitivity and specificity of the proposed 
screening criteria. 
In conclusion, we formulated novel criteria for screen-
ing for SHOX haploinsufficiency based on a cohort of 76 
patients with either intragenic SHOX defects or deletions 
of its enhancer region and 277 controls referred for short 
stature. The criteria are highly sensitive to detect SHOX 
haploinsufficiency within patients with short stature and 
facilitate the diagnosis, follow-up, and treatment of these 
patients and their affected relatives.
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